Круглый стол по материалам XIX Всероссийского научно-образовательного форума «Мать и Дитя» «Современная женщина: качество жизни, здоровье, красота»

1. Kerscher M. Effects of an oral contraceptive containing chlormadinone acetate and ethinylestradiol on hair and skin quality in women wishing to use hormonal contraception. J Eur Acad Dermatol Venereol 2013; 27 (5): 601–8.
2. Аганезова Н.В., Аганезов С.С. Комбинированные оральные контрацептивы: не только контрацепция. Акуш. и гинекол. 2015; 6: 118–23. / Aganezova N.V., Aganezov S.S. Kombinirovannye oral'nye kontratseptivy: ne tol'ko kontratseptsiia. Akush. i ginekol. 2015; 6: 118–23. [in Russian]
3. Reid RL, Westhoff C, Mansour D et al. Oral contraceptives and venous thromboembolism. Consensus opinion from an international workshop held in Berlin, Germany in December 2009. J Fam Plann Reprod Health Care 2010; 36: 117–22.
4. Прилепская В.Н., Межевитинова Е.А., Куземин А.А. Контрацепция и гиперандрогения. Клинические эффекты препарата, содержащего хлормадинона ацетат. Гинекология. 2015; 17 (4): 4–8. / Prilepskaya V.N., Mezhevitinovа E.A., Kuzemin A.A. Contraception and hyperandrogenism. Clinical effects of a drug containing chlormadinone acetate. Gynecology. 2015; 17 (4): 4–8. [in Russian]
5. Oral contraceptive containing chlormadinone acetate and ethinylestradiol reduces plasma concentrations of matrix metalloproteinase-2 in women with polycystic ovary syndrome. Gomes VA Basic Clin Pharmacol Toxicol 2012; 111 (3): 211–6.
6. Zahradnik HP, Hanjalic-Beck. Ecacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage – an open-label, prospective, noncontrolled, oce-based Phase III study. Contraception 2008; 77 (5): 337–43.
7. Jaisamrarn U, Santibenchakul S. A comparison of combined oral contraceptives containing chlormadinone acetate versus drospirenone for the treatment of acne and dysmenorrhea: a randomized trial. Contracept Reprod Med 2018; 3: 5.
8. Plewig G, Cunliffe WJ, Binder N et al. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial. Contraception 2009; 80 (1): 25–33.
9. Зильберберг Н.В., Толстая А.И. Оценка эффективности и безопасности препарата Белара в комплексной терапии больных акне. Фарматека. 2015; с. 40–5. / Zil'berberg N.V., Tolstaia A.I. Otsenka effektivnosti i bezopasnosti preparata Belara v kompleksnoi terapii bol'nykh akne. Farmateka. 2015; s. 40–5. [in Russian]
10. Anthuber S, Schramm GA, Heskamp ML. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study. Clin Drug Invest 2010; 30 (4): 211–20.

________________________________________________

1. Kerscher M. Effects of an oral contraceptive containing chlormadinone acetate and ethinylestradiol on hair and skin quality in women wishing to use hormonal contraception. J Eur Acad Dermatol Venereol 2013; 27 (5): 601–8.
2. Aganezova N.V., Aganezov S.S. Kombinirovannye oral'nye kontratseptivy: ne tol'ko kontratseptsiia. Akush. i ginekol. 2015; 6: 118–23. [in Russian]
3. Reid RL, Westhoff C, Mansour D et al. Oral contraceptives and venous thromboembolism. Consensus opinion from an international workshop held in Berlin, Germany in December 2009. J Fam Plann Reprod Health Care 2010; 36: 117–22.
4. Prilepskaya V.N., Mezhevitinovа E.A., Kuzemin A.A. Contraception and hyperandrogenism. Clinical effects of a drug containing chlormadinone acetate. Gynecology. 2015; 17 (4): 4–8. [in Russian]
5. Oral contraceptive containing chlormadinone acetate and ethinylestradiol reduces plasma concentrations of matrix metalloproteinase-2 in women with polycystic ovary syndrome. Gomes VA Basic Clin Pharmacol Toxicol 2012; 111 (3): 211–6.
6. Zahradnik HP, Hanjalic-Beck. Ecacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage – an open-label, prospective, noncontrolled, oce-based Phase III study. Contraception 2008; 77 (5): 337–43.
7. Jaisamrarn U, Santibenchakul S. A comparison of combined oral contraceptives containing chlormadinone acetate versus drospirenone for the treatment of acne and dysmenorrhea: a randomized trial. Contracept Reprod Med 2018; 3: 5.
8. Plewig G, Cunliffe WJ, Binder N et al. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial. Contraception 2009; 80 (1): 25–33.
9. Zil'berberg N.V., Tolstaia A.I. Otsenka effektivnosti i bezopasnosti preparata Belara v kompleksnoi terapii bol'nykh akne. Farmateka. 2015; s. 40–5. [in Russian]
10. Anthuber S, Schramm GA, Heskamp ML. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study. Clin Drug Invest 2010; 30 (4): 211–20.